Modulation of Glucose Homeostasis, Metabolic Endotoxemia and Circulating Short-Chain Fatty Acids Following Multi-Species Probiotic Supplementation: Findings from a 12-Week Randomised Placebo-Controlled Trial.

2026-03-24
Nutrients 18(7)

PubMed: 41978077
DOI: 10.3390/nu18071025

Study Design

Type: Randomized Controlled Trial (RCT)
Sample size: n = 39
Population: 39 adults with subthreshold depression
Methods: 12-week double-blind, randomised, placebo-controlled trial; 39 adults were allocated to either a probiotic supplement containing Limosilactobacillus fermentum LF16, Lacticaseibacillus rhamnosus LR06, Lactiplantibacillus plantarum LP01 and Bifidobacterium longum 04 or placebo; fasting glucose, insulin, HOMA-IR, GIP, hs-CRP, LBP, sCD14 and SCFAs were evaluated at baseline, week 6 and week 12

Rigorous Journal

Background: Altered gut microbiota and gut-derived inflammation impair glucose regulation and promote metabolic endotoxemia, yet evidence on probiotic effects across combined glycaemic, inflammatory and short-chain fatty acid (SCFA) outcomes remains limited. This study investigated the effects of a 12-week multi-species probiotic on glucose homeostasis, incretin hormones, inflammatory biomarkers and circulating SCFAs in adults with subthreshold depression. Methods: In a 12-week double-blind, randomised, placebo-controlled trial, 39 adults with subthreshold depression were allocated to either a probiotic supplement containing Limosilactobacillus fermentum LF16, Lacticaseibacillus rhamnosus LR06, Lactiplantibacillus plantarum LP01 and Bifidobacterium longum 04 (n = 19) or placebo (n = 20). Fasting glucose, insulin, HOMA-IR, glucose-dependent insulinotropic peptide (GIP), high-sensitivity C-reactive protein (hs-CRP), lipopolysaccharide-binding protein (LBP), soluble CD14 (sCD14) and SCFAs were evaluated at three time points: baseline, week 6 and week 12. Between-group and treatment × time effects were analysed using general linear models. Results: Probiotic supplementation significantly reduced fasting glucose at 12 weeks compared with placebo (-1.8 vs. 0.1 mmol/L; p = 0.036). In the probiotic group, greater reductions in GIP (p = 0.012; p = 0.037), LBP (p < 0.001), sCD14 (p = 0.002; p = 0.001) and hs-CRP (p = 0.047) were also observed compared with placebo. Plasma SCFA concentrations remained largely unchanged, with no significant treatment × time interactions, except for higher valerate levels at 12 weeks in the probiotic group (p = 0.019). Conclusions: Twelve weeks of multi-species probiotic supplementation improved fasting glucose, reduced incretin and inflammatory biomarkers and attenuated metabolic endotoxemia, without alterations in circulating SCFAs. These findings support beneficial modulation of metabolic-immune pathways and highlight the promising role of probiotics to enhance glucose regulation and systemic inflammatory tone in adults with subthreshold depression.

Research Insights

Supplement	Dose	Health Outcome	Effect Type	Effect Size	Source
Lactobacillus plantarum LP01	—	Improved Fasting Glucose Levels	Beneficial	Small	View source Probiotic supplementation significantly reduced fasting glucose at 12 weeks compared with placebo (-1.8 vs. 0.1 mmol/L; p = 0.036).
Lactobacillus plantarum LP01	—	Reduced Inflammatory Blood Markers	Beneficial	Small	View source greater reductions in ... LBP (p < 0.001), sCD14 (p = 0.002; p = 0.001) and hs-CRP (p = 0.047) were also observed compared with placebo.
Lactobacillus plantarum LP01	—	Reduced Metabolic Endotoxemia	Beneficial	Small	View source In the probiotic group, greater reductions in ... LBP (p < 0.001), sCD14 (p = 0.002; p = 0.001) ... were also observed compared with placebo.
Lactobacillus rhamnosus LR06	—	Improved Glucose Regulation	Beneficial	Small	View source Probiotic supplementation significantly reduced fasting glucose at 12 weeks compared with placebo (-1.8 vs. 0.1 mmol/L; p = 0.036).
Lactobacillus rhamnosus LR06	—	Reduced GIP	Beneficial	Small	View source In the probiotic group, greater reductions in GIP (p = 0.012; p = 0.037) ... were also observed compared with placebo.
Lactobacillus rhamnosus LR06	—	Reduced Inflammation	Beneficial	Small	View source In the probiotic group, greater reductions in ... hs-CRP (p = 0.047) were also observed compared with placebo.
Lactobacillus rhamnosus LR06	—	Reduced Metabolic Endotoxemia	Beneficial	Small	View source In the probiotic group, greater reductions in ... LBP (p < 0.001), sCD14 (p = 0.002; p = 0.001) ... were also observed compared with placebo.